Kristina Masson, EVP - Business Operations at Acrivon Therapeutics, sold ACRV on Aug 18, 2026
Data as of Oct 16
▼ SELL$973484 shares at $2.01Kristina Masson EVP - Business OperationsACRV Acrivon Therapeutics, Inc.
- Traded
- Aug 18, 2026
- Disclosed
- Aug 20, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ACRV since disclosure
−25.5%
after the sale
Similar stocks (XLV) since disclosure
+2.5%
XLV — its sector index fund
Change in closing price from Aug 20, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLKristina Masson EVP - Business OperationsACRV Acrivon Therapeutics, Inc.$2.5Kdisclosed Aug 20 · filed 2 days after the trade
- ▼ SELLPeter Blume-Jensen President and CEOACRV Acrivon Therapeutics, Inc.$2.5Kdisclosed Aug 20 · filed 2 days after the trade
- ▼ SELLPeter Blume-Jensen President and CEOACRV Acrivon Therapeutics, Inc.$973disclosed Aug 20 · filed 2 days after the trade